Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Assets (2020 - 2025)

Historic Assets for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $1.1 billion.

  • Apellis Pharmaceuticals' Assets rose 1739.25% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 1739.25%. This contributed to the annual value of $885.1 million for FY2024, which is 1221.22% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Assets stood at $1.1 billion, which was up 1739.25% from $821.4 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Assets registered a high of $1.1 billion during Q1 2022, and its lowest value of $525.7 million during Q3 2021.
  • Its 5-year average for Assets is $863.7 million, with a median of $872.9 million in 2022.
  • Its Assets has fluctuated over the past 5 years, first tumbled by 3158.07% in 2021, then surged by 6604.72% in 2022.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Assets stood at $881.8 million in 2021, then fell by 13.78% to $760.2 million in 2022, then increased by 3.75% to $788.7 million in 2023, then increased by 12.21% to $885.1 million in 2024, then increased by 19.62% to $1.1 billion in 2025.
  • Its Assets stands at $1.1 billion for Q3 2025, versus $821.4 million for Q2 2025 and $807.3 million for Q1 2025.